Q4 EPS Estimates for Zimmer Biomet Raised by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Stock analysts at Zacks Research upped their Q4 2024 EPS estimates for shares of Zimmer Biomet in a research note issued to investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings per share of $2.29 for the quarter, up from their prior forecast of $2.26. The consensus estimate for Zimmer Biomet’s current full-year earnings is $7.99 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q2 2025 earnings at $2.13 EPS and Q1 2026 earnings at $2.28 EPS.

Zimmer Biomet (NYSE:ZBH) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.80 billion. During the same quarter in the prior year, the company earned $1.65 earnings per share. Zimmer Biomet’s revenue was up 4.1% on a year-over-year basis.

Several other research analysts also recently commented on ZBH. Evercore ISI dropped their price objective on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a report on Tuesday, October 1st. JPMorgan Chase & Co. cut their target price on shares of Zimmer Biomet from $125.00 to $120.00 and set a “neutral” rating on the stock in a research report on Monday, September 16th. Wolfe Research started coverage on Zimmer Biomet in a report on Tuesday, September 10th. They issued a “peer perform” rating for the company. BTIG Research lowered their price target on shares of Zimmer Biomet from $134.00 to $126.00 and set a “buy” rating on the stock in a report on Thursday, October 3rd. Finally, Oppenheimer decreased their price objective on shares of Zimmer Biomet from $145.00 to $135.00 and set an “outperform” rating for the company in a research report on Tuesday, October 15th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, Zimmer Biomet has a consensus rating of “Hold” and a consensus price target of $123.22.

Zimmer Biomet Stock Performance

Shares of NYSE ZBH opened at $110.64 on Monday. The stock has a market cap of $22.03 billion, a PE ratio of 21.03, a price-to-earnings-growth ratio of 2.03 and a beta of 1.02. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.36 and a quick ratio of 0.70. The firm has a fifty day moving average price of $106.95 and a 200-day moving average price of $109.47. Zimmer Biomet has a 1 year low of $101.47 and a 1 year high of $133.90.

Institutional Investors Weigh In On Zimmer Biomet

A number of hedge funds have recently added to or reduced their stakes in ZBH. Wilmington Savings Fund Society FSB increased its holdings in shares of Zimmer Biomet by 7.7% in the 3rd quarter. Wilmington Savings Fund Society FSB now owns 6,196 shares of the medical equipment provider’s stock valued at $669,000 after acquiring an additional 442 shares during the last quarter. Sanctuary Advisors LLC lifted its holdings in Zimmer Biomet by 26.9% in the third quarter. Sanctuary Advisors LLC now owns 17,825 shares of the medical equipment provider’s stock valued at $1,965,000 after acquiring an additional 3,776 shares during the period. Toronto Dominion Bank lifted its position in shares of Zimmer Biomet by 14.5% during the 3rd quarter. Toronto Dominion Bank now owns 68,747 shares of the medical equipment provider’s stock valued at $7,421,000 after acquiring an additional 8,710 shares during the period. Neo Ivy Capital Management purchased a new stake in shares of Zimmer Biomet in the 3rd quarter worth about $150,000. Finally, Brown Financial Advisors lifted its stake in Zimmer Biomet by 16.6% in the 3rd quarter. Brown Financial Advisors now owns 9,566 shares of the medical equipment provider’s stock valued at $1,033,000 after buying an additional 1,361 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Zimmer Biomet Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.24 dividend. The ex-dividend date was Monday, September 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.87%. Zimmer Biomet’s dividend payout ratio is presently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.